Hipertrigliceridemia, esteatosis hepática y riesgo cardiovascular

  1. Brea Hernando, Ángel
  2. Mosquera Lozano, José Daniel
  3. Mostaza Prieto, José María
  4. Aranda Arcas, José Luis
  5. Argimón, Jordi
  6. Sanclemente, Carmen
  7. Mateo Gallego, Rocío
  8. Almagro, Fátima
  9. Plana Gil, Núria
  10. Recarte García Andrade, Carlos
Journal:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168 1578-1879

Year of publication: 2011

Volume: 23

Issue: 2

Pages: 72-77

Type: Article

More publications in: Clínica e investigación en arteriosclerosis

Abstract

Objectives: Nonalcoholic fatty liver disease (NAFLD) has been associated with both hypertriglyceridemia and an increased risk of cardiovascular complications. The aim of our study was to assess factors related to the presence of NAFLD in patients with hypertriglyceridemia and to calculate their Framingham score risk. Patients and methods: A total of 1.394 subjects (mean age 50.3 ± 12.4 years, 74.1% male) participating in the Hypertriglyceridemia Register of the Spanish Society of Arteriosclerosis were studied. Hypertriglyceridemia was considered as a triglyceride concentration =200 mg/dL confirmed on two different occasions. Liver steatosis was diagnosed by ultrasound. NAFLD was defined as the presence of steatosis in patients who were moderate alcohol consumers or abstainers. Results: Of the 649 subjects included in the final sample, 321 (49.5%) had NAFLD. As expected, liver enzymes were higher in this population. The presence of NAFLD was associated with a higher body mass index (p < 0.001), increased waist circumference (p < 0.001) and a higher prevalence of metabolic syndrome (p < 0.001). No differences in triglyceride concentration or in the prevalence of diabetes were found between subjects with and without NAFLD. A Framingham risk score above 20% was observed in 52.4% of the participants, with no differences in relation to NAFLD status. Conclusions: Hypertriglyceridemic subjects with NAFLD have a higher prevalence of obesity, mainly abdominal, and metabolic syndrome. The estimated cardiovascular risk in this population is very high but does not differ according to the presence of NAFLD.